AUSTRALIAN research published this week in The American Chemical Society’s Journal of Medicinal Chemistry describes a new radiopharmaceutical tracer which promises to give clearer pictures of melanoma and could lead to improved disease treatment.
08/10/2009
RESEARCHERS from the National Cancer Institute’s Centre for Cancer Research have identified a gene called PTEN which may play an important role in the formation of melanoma.
27/03/2009
Recent developments in RNAi, particularly in the design of lentiviral-based short hairpin RNA (shRNA), now allow researchers to potentially develop diagnostic and prognostic strategies for treating cancer and metastasis.
03/11/2009
RESEARCHERS claim to have developed a mouse model that allows them to replicate normal pigment cells at the earliest stages of their conversion into malignant skin cancer in humans.
17/03/2009
GAVIN Robertson, associate professor of pharmacology, pathology and dermatology, Penn State College of Medicine says his team have developed drugs from naturally occurring compounds that can inhibit the growth of tumours in mice by 50 to 60% with a very low dose.
13/03/2009
BIOMEDICAL researchers from Monash University and the University of Melbourne are developing peptides as vaccines against melanoma.
25/06/2009
The Federal Government will provide AUD$150 million to boost Australia's health and medical research efforts. Some of the projects funded include research into malaria, epilepsy, finding a treatment for stuttering, and respiratory support for preterm babies.
26/02/2010
CANCER Research UK Centre for Genetic Epidemiology, University of Cambridge has purchased Fluidigm Europe’s EP1 System in order to conduct cancer research and disease association studies.
29/05/2009
RESEARCHERS at the University of Michigan have identified a series of genes that become fused when their chromosomes trade places with each other, thought to be the reason why certain cancers develop.
12/01/2009
RESEARCHERS at the Institut de recherches cliniques de Montréal (IRCM) have identified a molecule which increases the function of Natural Killer cells (NK cells).
21/01/2009
NEW data from a meta-analysis of trials evaluating the addition of Merck KGaA’s Erbitux (cetuximab) to standard first-line chemotherapy in patients with non-small cell lung cancer (NSCLC) has been presented at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer (WCLC) in San Francisco.
04/08/2009